The P-III (ADJUVANT BR.31) study, funded by the Canadian Cancer Trials Group, assessed adj. Imfinzi vs PBO among Stage IB (≥4cm), II or IIIA NSCLC patients (n=1,415) post complete tumor resection, with/without adj. CT
Study did not reach its 1EP of DFS specifically in patients with PD-L1-expressing tumors. The safety profile aligned with the previous studies without any new safety outcomes; data will be highlighted at future conferences
In addition, Imfinzi is further being assessed under the PACIFIC-4 study alone or in combinations for inoperable or unresected Stage I-II NSCLC as well as PACIFIC-5, 8 and 9 for Stage III NSCLC
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Imfinzi Combined with Chemotherapy Gains the US FDA’s Approval to Treat Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
